<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:bovine-ojs-tamu.tdl.org:article/2244</identifier>
				<datestamp>2021-08-28T01:41:29Z</datestamp>
				<setSpec>bovine:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Efficacy and long-lasting activity of spiramycin in young beef cattle with infectious enzootic broncho-pneumonia</dc:title>
	<dc:creator xml:lang="en">Alzieu, J. P.</dc:creator>
	<dc:creator xml:lang="en">Bichet, H. J.</dc:creator>
	<dc:creator xml:lang="en">Levrier, B.</dc:creator>
	<dc:creator xml:lang="en">Van Gool, F.</dc:creator>
	<dc:creator xml:lang="en">Bayle, R.</dc:creator>
	<dc:creator xml:lang="en">Libersa, M.</dc:creator>
	<dc:creator xml:lang="en">Espinasse, J.</dc:creator>
	<dc:subject xml:lang="en">Antibiotics</dc:subject>
	<dc:subject xml:lang="en">Bacterial diseases</dc:subject>
	<dc:subject xml:lang="en">bronchitis</dc:subject>
	<dc:subject xml:lang="en">cattle diseases</dc:subject>
	<dc:subject xml:lang="en">Pneumonia</dc:subject>
	<dc:subject xml:lang="en">Respiratory diseases</dc:subject>
	<dc:subject xml:lang="en">spiramycin</dc:subject>
	<dc:subject xml:lang="en">aminoglycoside antibiotics</dc:subject>
	<dc:subject xml:lang="en">macrolide antibiotics</dc:subject>
	<dc:description xml:lang="en">Multicentric clinical trials performed in young beef cattle with I.E.B.P. demonstrated the excellent efficacy of spiramycin at an optimum dose of 100?000 IU/kg. The recommended frequency of administration in curative treatment is 2 injections at a 48 hour interval and the clinical recovery rate is 80-90%. A single injection of 100?000 IU/kg confers very high protection in metaphylactic treatment. The activity of spiramycin against Mycoplasma and Pasteurella, the principal agents involved in I.E.B.P., may be explained by the excellent diffusion and concentration of this antibiotic in the lung tissue and bronchial secretions.</dc:description>
	<dc:publisher xml:lang="en">American Association of Bovine Practitioners</dc:publisher>
	<dc:date>1989-11-01</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://bovine-ojs-tamu.tdl.org/bovine/article/view/2244</dc:identifier>
	<dc:identifier>10.21423/bovine-vol0no24p38-41</dc:identifier>
	<dc:source xml:lang="en">The Bovine Practitioner; No. 24 (1989 November); 38-41</dc:source>
	<dc:source>0524-1685</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://bovine-ojs-tamu.tdl.org/bovine/article/view/2244/2236</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 1989 American Association of Bovine Practitioners</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
